Quarterly ResultMay 14, 2026, 04:15 PM
Medicus Pharma Q1 Net Loss $(9.04)M; Going Concern Warning
AI Summary
Medicus Pharma Ltd. reported a net loss of $(9.04) million for Q1 2026, a significant increase from $(5.10) million in Q1 2025. The company's cash and cash equivalents decreased to $6.37 million from $8.71 million at year-end 2025. Management expressed substantial doubt about the company's ability to continue as a going concern, despite raising $6.83 million from financing activities, including common share issuances under SEPA and ATM programs.
Key Highlights
- Net loss for Q1 2026 increased to $(9.04) million from $(5.10) million in Q1 2025.
- Cash and cash equivalents decreased to $6.37 million as of March 31, 2026, from $8.71 million at December 31, 2025.
- Total operating expenses rose to $8.60 million in Q1 2026 from $5.13 million in Q1 2025.
- Net cash used in operating activities increased to $(8.97) million in Q1 2026 from $(3.94) million in Q1 2025.
- Net cash provided by financing activities was $6.83 million in Q1 2026, including $4.10 million from SEPA and $5.91 million from ATM.
- The company repaid $3.18 million in debentures and other loans during Q1 2026.
- Subsequent to quarter-end, the ATM program was upsized to $50 million, with $5.37 million raised.
- Management identified substantial doubt about the company's ability to continue as a going concern.